Co-Diagnostics, Inc. Common Stock (CODX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $2.72M
Last updated: Nov 17, 2026 at 4:39 PM ET
Co-Diagnostics, Inc. Common Stock (CODX) Statistics
Co-Diagnostics, Inc. Common Stock (CODX) has a market cap of $2.72M and an enterprise value of $2.00M. It kept -5527.61% of revenue as net income over the last 12 months. Revenue grew 69.11% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 26.29% below the market cap, as cash exceeds debt.
| Market Cap | $2.72M |
|---|---|
| Enterprise Value | $2.00M |
| Latest price (Nov 17, 2026) | $0.20 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.4x and 0.1x. Its year-end P/S ranged from 2.4x to 81.6x from 2019 to 2025.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 4.2x |
| P/B Ratio | 0.1x |
| P/TBV Ratio | 0.6x |
Price Statistics
The stock is down 98.03% over 52 weeks and trades 73.68% below its 50-day average.
| Beta (1Y) | 2.57 |
|---|---|
| 52-Week Change | -98.03% |
| 1-Month Change | -70.57% |
| 3-Month Change | -82.18% |
| 6-Month Change | -90.05% |
| 5-Year Change | -99.85% |
| Total Return (1Y) | -98.03% |
| Total Return (3Y CAGR) | -83.20% |
| Total Return (5Y CAGR) | -76.51% |
| Max Drawdown (1Y) | -98.31% |
| Max Drawdown (3Y) | -99.63% |
| Sharpe Ratio (1Y) | -1.93 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $0.76 |
| 200-Day Average | $2.05 |
| 52-Week Range | $0.22 to $13.54 |
| RSI (14 Days) | 20.6 |
| Average Volume (20 Days) | 5.67M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.77x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.77x |
|---|---|
| Quick Ratio | 0.50x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -503.71% over the last 12 months, against a 5-year average of -64.69%.
| Return on Equity (ROE) | -503.71% |
|---|---|
| Return on Assets (ROA) | -371.14% |
| ROE (5Y Average) | -64.69% |
| ROA (5Y Average) | -54.90% |
| Asset Turnover | 0.03x |
| Inventory Turnover | 0.90x |
| Receivables Turnover | 16.54x |
| Cash Conversion Cycle | -111 days |
Scores
CODX has an Altman Z-Score of -23.38, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -23.38 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $858.89K over the last 12 months.
| Revenue | $858.89K |
|---|---|
| Revenue Growth (YoY) | +69.11% |
| Gross Profit | $174.08K |
| Operating Income | -$48.22M |
| Pretax Income | -$47.93M |
| Net Income | -$47.48M |
| EBITDA | -$47.28M |
| Reported EPS (TTM) | -$11.00 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 73.73% of the $12.79M in total assets.
| Cash and Equivalents | $714.80K |
|---|---|
| Total Debt | $0 |
| Net Cash | $714.80K |
| Net Cash Per Share | $0.11 |
| Working Capital | -$573.72K |
| Shareholder Equity | $9.43M |
| Book Value Per Share | $1.50 |
| Tangible Book Value | $2.21M |
| Tangible Book Per Share | $0.35 |
| Total Assets | $12.79M |
| Total Liabilities | $3.37M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $307.27K of capital spending, operating cash flow left -$27.19M of free cash flow.
| Operating Cash Flow | -$26.88M |
|---|---|
| Capital Expenditures | $307.27K |
| Free Cash Flow | -$27.19M |
| FCF Per Share | -$3.08 |
| Depreciation and Amortization | $947.21K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5614.27%.
| Gross Margin | 20.27% |
|---|---|
| Operating Margin | -5614.27% |
| Pretax Margin | -5580.41% |
| Net Margin | -5527.61% |
| EBITDA Margin | -5504.44% |
| FCF Margin | -3165.71% |
| Gross Margin (5Y Average) | 69.90% |
Growth
Revenue fell 73.70% a year over 3 years.
| Revenue Growth (3Y CAGR) | -73.70% |
|---|---|
| Revenue Growth (5Y CAGR) | -61.60% |
Dividends and Yields
CODX does not pay a dividend. Its free cash flow yield is -2211.57%.
| FCF Yield | -2211.57% |
|---|---|
| Buyback Yield | -1366.13% |
| Shareholder Yield | -1366.13% |
Stock Splits
The last split was a 1-for-30 reverse split on Jan 2, 2026.
| Last Split Date | Jan 2, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 7 similar companies, CODX has the 3rd highest P/S.
P/S RatioPeer median 0.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +27.56%
| P/S Ratio | 1.4x vs 0.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +69.11% vs +27.56% median |
Analyst Forecast
Consensus estimates put revenue growth at 427.30% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +427.30% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CODX
What is CODX's market cap?
Co-Diagnostics, Inc. Common Stock has a market cap of $2.72M. Its enterprise value, which adds debt and subtracts cash, is $2.00M.
How many shares of CODX are outstanding?
Co-Diagnostics, Inc. Common Stock has 6.27M shares outstanding.
Does CODX pay a dividend?
No. Co-Diagnostics, Inc. Common Stock does not pay a dividend.
How much debt does CODX have?
Co-Diagnostics, Inc. Common Stock has $0 of total debt and $714.80K of cash and equivalents, a net cash position of $714.80K.
CODX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors